News

Anjarium Biosciences appoints experienced industry executives Samantha Vieira as Chief Operating Officer and Nate Massari as Chief Business Officer

Schlieren, Zurich, 12 July 2022 – Anjarium Biosciences AG (“Anjarium”), a biotech company focused on creating and delivering a new class of non-viral gene therapies, today announces the expansion of its leadership team with the appointment of Samantha Vieira as Chief Operating Officer (COO) and Nate Massari as Chief Business...

read more

Proteomedix announces grant of U.S. patent on Proclarix®

Zurich-Schlieren, Switzerland, July 05, 2022. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, is pleased to announce that the United States Patent and Trademark Office granted to the company U.S. Patent No. 11,320,435, titled “Method of detecting proteins in human samples and uses of such methods” that...

read more

New results on Proclarix® resolving indeterminate Magnetic Resonance Imaging (MRI) for improved prostate cancer diagnosis will be presented at the 37th Annual EAU Congress in Amsterdam, NL.

Zurich-Schlieren, Switzerland, June 29, 2022. Proteomedix, a Swiss diagnostics company committed to advance prostate cancer care, today announced that new data will be presented showing that Proclarix® can be used with high confidence by reliably identifying clinically significant prostate cancer and safely ruling out negative cases. Study results will be presented...

read more

ImmunOs Therapeutics Raises $74 Million Series B Financing Round

Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – June 7, 2022 – ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced the closing of an oversubscribed Series B financing round totaling $74 million....

read more

Kuros Biosciences: Completion of the acquisition of Checkmate Pharmaceuticals by Regeneron Pharmaceuticals triggers a $5 million milestone payment

Schlieren (Zurich), Switzerland, June 2, 2022 – Kuros Biosciences AG (“Kuros” or the “Company”), a leader in next generation bone graft technologies, notes the completion of the acquisition of Checkmate Pharmaceuticals (NASDAQ: CMPI) by Regeneron Pharmaceuticals (NASDAQ: REGN). The completion triggers a $5 million milestone payment under a license agreement...

read more